VISIPAQUE 270 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Visipaque 270, and when can generic versions of Visipaque 270 launch?
Visipaque 270 is a drug marketed by Ge Healthcare and is included in two NDAs.
The generic ingredient in VISIPAQUE 270 is iodixanol. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the iodixanol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Visipaque 270
A generic version of VISIPAQUE 270 was approved as iodixanol by HENGRUI PHARMA on May 19th, 2022.
Summary for VISIPAQUE 270
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Clinical Trials: | 31 |
Patent Applications: | 4,055 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VISIPAQUE 270 at DailyMed |
Recent Clinical Trials for VISIPAQUE 270
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Institute of Liver and Biliary Sciences, India | N/A |
University of Washington | Phase 1 |
Guerbet | Phase 1 |
Pharmacology for VISIPAQUE 270
Drug Class | Radiographic Contrast Agent |
Mechanism of Action | X-Ray Contrast Activity |
Anatomical Therapeutic Chemical (ATC) Classes for VISIPAQUE 270
US Patents and Regulatory Information for VISIPAQUE 270
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | VISIPAQUE 270 | iodixanol | INJECTABLE;INJECTION | 020351-001 | Mar 22, 1996 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Ge Healthcare | VISIPAQUE 270 | iodixanol | INJECTABLE;INJECTION | 020808-001 | Aug 29, 1997 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VISIPAQUE 270
International Patents for VISIPAQUE 270
See the table below for patents covering VISIPAQUE 270 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 1057703 | ⤷ Try a Trial | |
Israel | 93752 | Contrast media containing sodium ions addition and non-ionic contrast agents | ⤷ Try a Trial |
Netherlands | 183121 | ⤷ Try a Trial | |
Canada | 2076861 | ⤷ Try a Trial | |
Finland | 923962 | ⤷ Try a Trial | |
Norway | 156317 | ⤷ Try a Trial | |
Latvia | 10058 | CONTRAST MEDIA AND PROCESS OF PREPARATION OF IT | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VISIPAQUE 270
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0108638 | SPC/GB93/150 | United Kingdom | ⤷ Try a Trial | SPC/GB93/150, 20031107, EXPIRES: 20080330 |
0108638 | 97C0101 | Belgium | ⤷ Try a Trial | PRODUCT NAME: IODIXANOL; NAT. REGISTRATION NO/DATE: 914 IS 204 F 12 19970325; FIRST REGISTRATION: SE 11758 19930205 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |